24.77 -0.39 (-1.55%) | 03-28 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 33.23 | 1-year : | 36.24 |
Resists | First : | 28.45 | Second : | 31.03 |
Pivot price | 26.28 | |||
Supports | First : | 24.29 | Second : | 20.2 |
MAs | MA(5) : | 25.2 | MA(20) : | 26.9 |
MA(100) : | 32.04 | MA(250) : | 48.12 | |
MACD | MACD : | -1.1 | Signal : | -1 |
%K %D | K(14,3) : | 7.5 | D(3) : | 10.5 |
RSI | RSI(14): 38.3 | |||
52-week | High : | 79.65 | Low : | 24.28 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PRTA ] has closed above bottom band by 25.7%. Bollinger Bands are 16.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 25.37 - 25.5 | 25.5 - 25.62 |
Low: | 23.93 - 24.08 | 24.08 - 24.23 |
Close: | 24.48 - 24.73 | 24.73 - 24.97 |
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
Wed, 27 Mar 2024
Prothena (PRTA) Alzheimer's Disease Drug Licensed by BMY - Yahoo Movies Canada
Mon, 25 Mar 2024
SG Americas Securities LLC Has $4.94 Million Holdings in Prothena Co. plc (NASDAQ:PRTA) - MarketBeat
Mon, 25 Mar 2024
SG Americas Securities LLC Acquires 43363 Shares of Prothena Co. plc (NASDAQ:PRTA) - Defense World
Fri, 23 Feb 2024
Prothena: Alzheimer's Data Update In 2024 Could Move The Needle (NASDAQ:PRTA) - Seeking Alpha
Fri, 16 Feb 2024
Prothena Corporation plc (NASDAQ:PRTA) Q4 2023 Earnings Call Transcript - Yahoo Finance
Thu, 08 Feb 2024
Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024 - Business Wire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 54 (M) |
Held by Insiders | 3.828e+007 (%) |
Held by Institutions | 12.4 (%) |
Shares Short | 5,750 (K) |
Shares Short P.Month | 0 (K) |
EPS | -1.9011e+008 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | -161 % |
Operating Margin | -24 % |
Return on Assets (ttm) | 846.5 % |
Return on Equity (ttm) | -16.5 % |
Qtrly Rev. Growth | 9.137e+007 % |
Gross Profit (p.s.) | -451.82 |
Sales Per Share | -112.96 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | -2.8 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -134 (M) |
PE Ratio | -0.01 |
PEG Ratio | -0.2 |
Price to Book value | 0 |
Price to Sales | -0.22 |
Price to Cash Flow | 0.52 |
Dividend | 0 |
Forward Dividend | 6.07e+006 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |